Zealand Pharma Plummets as Gastrointestinal Side Effects Cloud Survodutide’s Commercial Path
Table of Contents
Tolerability Hits the Bottom Line
Zealand Pharma saw its valuation crater by as much as 26% on Monday, a brutal reaction to new clinical data that suggests its experimental obesity treatment, survodutide, may be too difficult for a significant number of patients to tolerate. While the drug successfully met its primary weight-loss targets, the cost of that efficacy appears to be a high rate of severe gastrointestinal distress.
The Danish biotech company revealed that 19% of participants in a late-stage study dropped out specifically due to gastrointestinal events. To put that in perspective, only 2.9% of the placebo group left the study for similar reasons. The data paints a stark picture of the drug’s side-effect profile, with more than 40% of patients reporting vomiting—a metric that has sent investors fleeing.
For the markets, this isn’t just a clinical hiccup; it is a commercial red flag. Analysts at Barclays noted in a Monday briefing that safety and tolerability remain the primary hurdles for Zealand. In a crowded field where patients have multiple options, a high discontinuation rate significantly limits the drug’s viability for treating general obesity or non-alcoholic steatohepatitis (NASH), often referred to as fatty liver disease.
The ‘Weight Loss Olympics’ vs. Reality
The tension between raw efficacy and patient experience is currently the central conflict in the obesity drug market. Topline data from April indicated that survodutide could trigger an average weight loss of 16.6%, dwarfing the 3.2% seen in the placebo group. On paper, that is a victory. In practice, however, the clinical utility of a drug is measured by whether a patient can actually stay on it.
Citi analysts were blunt in their assessment, stating that a 19% discontinuation rate is “not a rounding error.” They argued that the incidence of nausea, vomiting, diarrhea, and constipation reported in the survodutide trials sits well above what they consider commercially viable when compared to the current industry gold standards: Eli Lilly’s tirzepatide (Zepbound/Mounjaro) and Novo Nordisk’s semaglutide (Wegovy/Ozempic).
This volatility comes at a precarious time for Zealand Pharma. The stock has already plummeted nearly 50% year-to-date. Just three months ago, the company suffered its worst trading day on record after another experimental drug, petrelintide, failed to wow investors with its weight-loss statistics. While petrelintide—developed in partnership with Roche—shows better tolerability, analysts suggest its efficacy is lacking compared to Lilly’s eloralintide.
A Crowded Field of Alternatives
Zealand is fighting for a foothold in a market currently dominated by a duopoly of Novo Nordisk and Eli Lilly. However, the periphery is filling up quickly. Heavyweights like Amgen and AstraZeneca are racing to develop next-generation treatments, shifting the focus from simple weight reduction to more nuanced goals, such as the preservation of lean muscle mass and the development of oral tablets to replace needles.
Interestingly, Zealand’s leadership has spent months arguing against the current industry obsession with total weight loss percentages—what CEO Adam Steensberg has termed the “weight loss olympics.” Speaking with CNBC in March, Steensberg insisted that the industry would eventually pivot toward tolerability as the primary metric of success.
The market’s reaction on Monday suggests that while Steensberg may be right about the long-term trend, investors are unwilling to wait for a shift in philosophy while the current data shows patients struggling to keep the medication down. The irony is sharp: the very “tolerability” shift the CEO championed has now become the company’s greatest liability.
